Neumora Therapeutics, Inc. (NMRA) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Neumora Therapeutics, Inc. (NMRA) Healthcare & Pipeline Overview

Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in developing and commercializing innovative therapies for brain diseases. Their pipeline, featuring navacaprant for major depressive disorder, positions them as a key player in addressing unmet needs within the neuropsychiatric and neurodegenerative disease landscape.

What Is the Investment Thesis for NMRA?

Neumora Therapeutics presents a notable research candidate due to its diversified pipeline of novel therapies targeting significant unmet needs in brain diseases. Navacaprant (NMRA-140), currently in Phase 3 trials for MDD, represents a near-term value driver. Positive trial outcomes and subsequent regulatory approval could lead to substantial revenue generation. The company's focus on precision medicine and targeted therapies, along with its early-stage assets like NMRA-511 and NMRA-266, offer long-term growth potential. However, the inherent risks associated with clinical-stage biopharmaceutical companies, including trial failures and regulatory hurdles, should be considered. With a market cap of $210M and a beta of 3.12, Neumora's stock exhibits high volatility, reflecting the speculative nature of its pipeline progress. Successful commercialization of its lead assets is crucial for realizing its long-term value.

Based on FMP financials and quantitative analysis

NMRA Key Highlights

Navacaprant (NMRA-140) is in Phase 3 clinical trials for the treatment of major depressive disorder, representing a potential near-term revenue driver.

• NMRA-511 is in Phase 1 clinical trials for agitation associated with dementia due to Alzheimer's disease, addressing a significant unmet need in the elderly population.
• NMRA-266 is in Phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders, expanding the company's focus to a broader range of mental health conditions.
• The company's preclinical pipeline includes programs targeting amyotrophic lateral sclerosis (ALS) and Parkinson's disease, indicating long-term growth potential in neurodegenerative diseases.
• Neumora Therapeutics operates with 110 employees, reflecting a focused and agile approach to drug development and clinical trials.

Who Are NMRA's Competitors?

NMRA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are NMRA's Key Strengths?

Diversified pipeline of novel therapies.

• Lead product candidate in Phase 3 clinical trials.
• Focus on precision medicine and targeted therapies.
• Experienced management team with expertise in drug development.

What Are NMRA's Weaknesses?

Clinical-stage company with no currently approved products.

• High dependence on clinical trial outcomes.
• Limited financial resources compared to larger pharmaceutical companies.
• High beta indicates significant stock volatility.

What Could Drive NMRA Stock Higher?

Topline results from Phase 3 clinical trials of navacaprant for major depressive disorder.

• Initiation of Phase 2 clinical trials for NMRA-511 in agitation associated with Alzheimer's disease.
• Advancement of preclinical programs targeting ALS and Parkinson's disease into Phase 1 clinical trials.
• Continued enrollment and data monitoring in ongoing clinical trials.
• Potential for strategic partnerships and licensing agreements.

What Are the Key Risks for NMRA?

Financial-distress signal — its Altman Z-Score of -17.27 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Failure of navacaprant in Phase 3 clinical trials.
• Regulatory delays or rejection of marketing applications.
• Competition from existing and emerging therapies.
• High cash burn rate associated with clinical development.
• Dependence on key personnel and intellectual property.

What Are the Growth Opportunities for NMRA?

• Positive Phase 3 trial results for navacaprant could lead to FDA approval and subsequent commercialization, providing a significant revenue stream for Neumora. The timeline for potential market entry is dependent on trial outcomes and regulatory review, but successful launch could establish Neumora as a key player in the MDD treatment landscape.
• NMRA-511 for Agitation Associated with Alzheimer's Disease: Agitation in Alzheimer's patients represents a substantial unmet need, with limited treatment options available. NMRA-511, currently in Phase 1 trials, targets this specific symptom. Successful development and approval could capture a significant share of the market for Alzheimer's-related behavioral disturbances. The timeline for commercialization depends on clinical trial progress and regulatory approval, potentially offering a mid- to long-term growth opportunity.
• NMRA-266 for Schizophrenia and Neuropsychiatric Disorders: The market for schizophrenia treatments is characterized by a need for more effective and tolerable therapies. NMRA-266, in Phase 1 trials, aims to address this need. Positive clinical trial results could position Neumora to compete in this market. The timeline for commercialization is longer-term, contingent on successful trial outcomes and regulatory approval, but represents a significant growth opportunity.
• Preclinical Programs in Neurodegenerative Diseases: Neumora's preclinical programs targeting amyotrophic lateral sclerosis (ALS) and Parkinson's disease represent long-term growth opportunities. These programs, including NMRA-CK1d for ALS and NMRA-GCase for Parkinson's, address diseases with significant unmet needs. While these programs are in early stages, successful development could lead to valuable therapies and partnerships, contributing to Neumora's long-term growth.
• Strategic Partnerships and Acquisitions: Neumora has the opportunity to expand its pipeline and capabilities through strategic partnerships, licensing agreements, or acquisitions. Collaborating with other biotech companies or research institutions could accelerate drug development and broaden its therapeutic focus. These partnerships could provide access to new technologies and expertise, enhancing Neumora's competitive position and growth prospects.

What Threats Does NMRA Face?

• Clinical trial failures.
• Regulatory hurdles and delays.
• Competition from established pharmaceutical companies.
• Patent expirations and generic competition.

What Are NMRA's Competitive Advantages?

• Proprietary drug candidates with patent protection.
• Clinical trial data demonstrating efficacy and safety.
• Expertise in neuropsychiatric and neurodegenerative drug development.
• Strategic focus on precision medicine and targeted therapies.
• Established partnerships with research institutions and key opinion leaders.

What Does NMRA Do?

Neumora Therapeutics, Inc., founded in 2019 and headquartered in Watertown, Massachusetts, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. Formerly known as RBNC Therapeutics, Inc., the company changed its name in October 2021 to reflect its focused mission. Neumora's pipeline includes a range of therapies targeting significant unmet needs in mental health and neurological disorders. Their lead product candidate, navacaprant (NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently in Phase 3 clinical trials for the treatment of major depressive disorder (MDD). Additionally, Neumora is developing NMRA-511, a therapeutic in Phase 1 clinical trials for agitation associated with dementia due to Alzheimer's disease. NMRA-266 is another key asset, undergoing Phase 1 clinical trials for the treatment of schizophrenia and other neuropsychiatric disorders. The company's preclinical programs include NMRA-NMDA for schizophrenia, NMRA-CK1d for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for neurodegenerative conditions, and NMRA-GCase for Parkinson's disease. Neumora's strategic focus on precision medicine and targeted therapies aims to improve outcomes for patients suffering from a wide array of brain-related disorders. With a team of 110 employees, Neumora is committed to advancing innovative science and addressing critical gaps in the treatment of neurological and psychiatric illnesses.

What Products and Services Does NMRA Offer?

• Develop novel therapeutic treatments for brain diseases.
• Focus on neuropsychiatric and neurodegenerative disorders.
• Advance navacaprant (NMRA-140) through Phase 3 clinical trials for major depressive disorder.
• Conduct Phase 1 clinical trials for NMRA-511 in Alzheimer's-related agitation.
• Develop NMRA-266 for the treatment of schizophrenia and other neuropsychiatric disorders.
• Advance preclinical programs targeting ALS and Parkinson's disease.
• Employ precision medicine approaches to target specific disease mechanisms.

How Does NMRA Make Money?

• Develop and patent novel therapeutic compounds.
• Conduct clinical trials to demonstrate safety and efficacy.
• Seek regulatory approval from agencies like the FDA.
• Commercialize approved therapies through sales and marketing efforts.
• Potentially out-license or partner with other companies for commercialization.

What Industry Does NMRA Operate In?

The biotechnology industry is characterized by high-risk, high-reward ventures focused on developing innovative therapies for unmet medical needs. The market for brain disease treatments is substantial, driven by an aging population and increasing prevalence of neuropsychiatric disorders. Neumora Therapeutics operates in a competitive landscape, facing established pharmaceutical companies and other biotech firms. The success of companies like Neumora hinges on their ability to navigate regulatory pathways, secure funding, and demonstrate clinical efficacy. The industry is witnessing a trend towards precision medicine and targeted therapies, aligning with Neumora's strategic focus.

Who Are NMRA's Key Customers?

• Patients suffering from major depressive disorder.
• Patients with agitation associated with Alzheimer's disease.
• Individuals diagnosed with schizophrenia and other neuropsychiatric disorders.
• Patients with amyotrophic lateral sclerosis (ALS).
• Individuals affected by Parkinson's disease.

Company Profile

Neumora Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Watertown, United States.

Neumora Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -17.27 places it in the distress zone, a signal of elevated financial risk.

Key Financial Metrics

Its free cash flow yield is -61.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.09 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -72.9%, the inverse of the P/E and a quick read on earnings relative to price.

NMRA Valuation & Market Position

With a $210M market cap, Neumora Therapeutics, Inc. sits in the micro-cap segment of the market. Analyst price targets span from $4.00 to $5.00, with a consensus of $4.50. At the current price of $1.14, that implies approximately 296% upside potential. Relative to its peer group, NMRA's quantitative score of 26/100 is below the peer average of 75/100.

Neumora Therapeutics, Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 1.7% above estimates on average.

Wall Street analysts project Neumora Therapeutics, Inc. revenue of about $625K for fiscal 2026, with EPS near $-0.91. The estimate reflects 9 contributing analysts.

Over the past six months, Neumora Therapeutics, Inc. insiders filed 30 SEC Form 4 transactions — 14 sales and 16 purchases. On net that is roughly 1.6M shares acquired (about $2.3M) — insiders putting money in tends to read as conviction.

NMRA Financials

NMRA Latest News

NMRA Analyst Consensus

NMRA MoonshotScore

NMRA Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources